替吉奧不同用藥方案及有效率匯總

1、替吉奧（S-1）不同用藥方案及有效率匯總表1替吉奧膠囊（S-1）用于胃癌用藥方案及有效率用藥方案用法用量RRMST參考文獻S-1S-1:40mg/m2,bid4W,q6w44.6%244dMaeharaY,GastricCancer.2003;6S-1+順柏S-1:40-60mg/m2,bid3W,q5w順鉗：60mg/m2,iv,D854%13.0mKoizumiW,ASCO,2008S-1+多西他賽S-1:40mg/m2,bid2W,q3w多西他賽：40mg/m2,iv,D156.3%14.3mKazuhiroYoshida,ClinCancer,Res2006;12(11):3402S-

2、1+順柏+多西他賽S-1:40mg/m2,bid2w,q2w順鉗:60mg/m2,iv,D1多西他賽:40mg/m2,iv,D182.5%N.Nakayama,etal.ASCO,2009S-1+伊立替康S-1:40-60mg/m2,bid3w伊立普康:80mg/m,iv,D1、1547.8%394dNoriyaUedo,etal.Oncology2007;73:65-71S-1+奧沙利伯S-1:40mg/m2,bid2w,q3w奧沙利鉗:100mg/m2,iv,D158.8%HTakiuchi,etal.ASCO,2009S-1+伊立替康+奧沙利伯S-1:40mg/m2,bid2w,q3w伊

3、立替康:150mg/m,iv,D1奧沙利鉗:85mg/m2,iv,D174.3%S.R.Park,ASCO,2008S-1+紫杉醇S-1:40mg/m2,bid2w,q3w紫杉醇ip,20mg/m2,iv,50mg/m2,D1、862%J.Kitayama,ASCO,2009表2替吉奧膠囊（S-1）用于結腸直腸癌用藥方案及有效率用藥方案用法用量RRmPFS,經受文獻S-1S-1:40-60mg/m2,bid4w,q6w35.5%OhtsuA,BrJCancer83:141-145S-1+伊立替康S-1:40-60mg/m2,bid2w,q3w伊立普康：150mg/m,D162.5%8.0mGo

4、toA.,AnnOncol,2006(17):968S-1+奧沙利伯S-1:40-60mg/m2,bid2w,q3w奧沙利鉗：100-130mg/m2,D150%196dBritishJournalofcancer,2008,98,1034-1038表3替吉奧（S-1）用于胰腺癌用藥方案及有效率用藥方案用法用量RRMST參考文獻S-1S-1:40-60mg/m2,bid4w,q6w37.5%9.2mCancerChemotherPharmacol.2008,61:615621S-1+吉西他濱S-1:30-40mg/m2,bid2w吉西他濱:800-1000mg/m2,D8、1548%12.5m

5、BritishJournalofCancer.2007,96:1353-1357S-1+放療S-1:30-40mg/m2,放療36%12.3mBritishJournalofCancer.2005,92:2134-2139表4替吉奧（S-1）用于非小細胞肺癌（NSCLC的臨床研究用藥方案及有效率用藥方案用法用量RRmOS參考文獻S-1S-1:40mg/m2,bid4W,q6w22.0%10.2mBritishJournalofCancer,2001,85:939S-1+順柏S-1:40mg/m2,bid3W,q5w順鉗：60mg/m2/d,D847.0%11mClinicalcanerrese

6、arch,2004,12:7860S-1:40mg/m2,bid3W,q5w順鉗：25mg/m2/d,D7、14、2123.1%13.4mLungCancer,2009,63:68S-1+順柏+胸腔放療S-1:30-40mg/m2,bid2w,q4w順鉗：30-50mg/m2/d,D1、8;胸腔放療86.4%24.4mLungCancer,65(2009):7429S-1:40mg/m2,bid2w,q4w順鉗：60mg/m2/d,D1胸腔放療87.5%33.1mOhyanagiF,etal.BrJCancer.2009,101(2):225-31S-1+伊立替康S-1:40mg/m2,bid

7、2w,q3w伊立普康：150mg/m/d,D128.6%15mOkamotoI,etal.ClinCancerRes.2008,14(16):5250S-1十多西他賽(已化療過的NSCLC患者)S-1:40mg/m2,bid2w,q3w多西他賽：40mg/m2,D124.1%11.8mAtagiS,etal.JThoracOncol.2008,3(9):1012-7表5替吉奧膠囊（S-1）用于乳腺癌用藥方案及有效率用藥方案用法用量RRMST參考文獻S-1S-1:40mg/m2,bid4w,q6w41.7%872dBreastCancer,2004,11(2):194S-1:40-60mg/m2

8、/d,bid4w,q6w42%910dSaekiT,etal.GanToKagakuRyoho.2004,31(4):539-47表6替吉奧（S-1）用于頭頸部癌用藥方案及有效率用藥方案RR參考文獻S-128.8%InuyamaY,Cancer&chemotherapy,2001;28(10):1381S-1+順柏67.6%FujiiM.GanToKagakuRyoho.2006,33Suppl1:150S-1+卡柏40.9%AkihitoWatanabe,WileyInterScience,2006:620-625表7替吉奧（S-1）用于轉移性或復發(fā)性膽管癌用藥方案及有效率用藥方案用

9、法用量RRmOS參考文獻S-1S-1:40mg/m2,bid4w,q6w21.1%8.3mUenoH,OkusakaT,etal.BrJCancer.2004Nov15;91(10):1769-74S-1+順柏S-1:40mg/m2,bid2w,q3w順鉗：60mg/m2,iv,D130%8.7mKimYJ,ImSA,etal.AnnOncol.2008Jan;19(1):99-103.Epub2007Sep9S-1+吉西他濱S-1:40mg/m2,bid2w吉西他濱：1000mg/m2,D1,D15,q4w34.3%11.6mTakashiSasaki,HiroyukiIsayamaetal.CancerChemotherapyandPharmacology,2009說明：以上圖表中，S-1指替吉奧膠囊；RR指有效率；MST指中位生存時間；244d指244天；13.0m指13.0個月；40mg/m指根據(jù)患者體表面積用藥，替吉奧一次用量40mg每平方米；bidX2w指一天兩次用藥（bid）,連續(xù)用藥2周；q